A drug previously approved for adults with certain types of lymphoma or leukemia has become the first FDA approved medication for chronic graft-vs-host disease (GVHD).
A drug previously approved for adults with certain types of lymphoma or leukemia has become the first FDA approved medication for chronic graft-vs-host disease (GVHD).